

## **Chemotherapy Checklist**

The Eviti online treatment plan requires the following information.

Patient name:		DOB:	
Insurance plan:		Insurance ID:	
Patient ZIP Code:		Date of diagnosis:	
Physician name:			
Practice tax ID:	Ph	nysician NPI:	
Submitter name:			
Submitter phone:	Fax:	Email:	
	Patient <sup>-</sup>	Treatment Details	
Patient height:		Patient weight:	□lb /□ kg
Cancer type (site):		ICD-10 code:	
Pathology:			
Current stage of disease: (e.g. Stage	IIa, Recurrent)		
If applicable: Metastasis site(s):		Metastasis diagnosis date:	
Line of therapy: (select one) □Adjuv	⁄ant □Neoadjı	uvant □1 <sup>st</sup> line □2 <sup>nd</sup> line □ 3 <sup>rd</sup> lin	e □ 3 <sup>rd</sup> +
Goal of therapy/intent: (select one)	☐ Curative	☐ Non-Curative	
Total # cycles planned:		Cycle length (days):	
Is this a clinical trial? ☐Yes ☐No	Clinical trial	ID or name:	
Treatment start date (C1D1):		Give until progress	sion: □Yes □No
Regimen name (e.g. R-CHOP, TAC):			



## Chemotherapy Drug Details

Include all IV and oral medications in the regimen (chemotherapy, targeted therapy, pre-meds, antiemetics, growth factor injections and or other supportive meds) in one preauthorization. Refer to the chemotherapy orders. Attach a document with additional drugs, if necessary.

<b>Drug name</b> Indicate if IV or oral	Dose and units (e.g. 60 mg/m2)	Delivered dose (e.g. 120 mg)	Schedule (e.g. D1, D1-3)	J-code
Site of service: ( <i>select one</i> )  □ Inpa	tient □ Outpatient			
Site name:	Site o	city or ZIP Code:		
Site TIN:	Site N	NPI:		
Medication source: ( <i>select one</i> ) ☐ Phar	macy 🔲 Buy and bill			

following documents to the online treatment plan:

If you do not receive an automated Eviti code, the request goes to Eviti for review. Please attach the

- Progress note(s) with plan of care
- Pathology
- Recent lab reports (i.e. CBC, ANC)
- Scans if relative to this treatment plan
- Chemotherapy checklist
- Genomic test report, if applicable
- Any information that addresses the issues noted on the Deviation Report

If you don't attach the documents online, you can email them to <a href="mr@eviti.com">mr@eviti.com</a> or fax them to 888-468-1423. If faxing, please use the Eviti-generated QR coded cover sheet.



## Molecular Marker Results

If molecular marker testing was done, please select the results. Ask a clinical person to help complete this section, if necessary.

Cancer type	Molecular marker	Select or provide re	sult	
Adrenal	Microsatellite Instability	□MSI-L □Unknown	□dMMR/MSI-H	□Not Reported
	NTRK Fusion	□Positive □Unknown	□Negative	□Not Reported
Anal	BRAF Status	□V600E Mutation □Wild Type	□V600K Mutation □Not Reported	□Unknown
	k-ras Genotype	□Wild Type □Unknown	□Mutated	□Not Reported
	Microsatellite Instability	□MSI-L □Unknown	□dMMR/MSI-H	□Not Reported
	n-ras Genotype	□Wild Type □Unknown	□Mutated	□Not Reported
	NTRK Fusion	□Positive □Unknown	□Negative	□Not Reported
Bile Duct (extrahepatic)	Margin status	□Positive □Unknown	□Negative	□Not Reported
	Nodal status	□Positive □Unknown	□Negative	□Not Reported
	Microsatellite Instability	□MSI-L □Unknown	□dMMR/MSI-H	□Not Reported
	NTRK Fusion	□Positive □Unknown	□Negative	□Not Reported
Biliary Tract (intrahepatic)	Margin Status	□Positive □Unknown	□Negative	□Not Reported
	Microsatellite Instability	□MSI-L □Unknown	□dMMR/MSI-H	□Not Reported
	NTRK Fusion	□Positive □Unknown	□Negative	□Not Reported
Bladder	Microsatellite Instability	□MSI-L □Unknown	□dMMR/MSI-H	□Not Reported
	Platinum Resistant/Refractory	□Yes □No	□Not Reported	□Unknown



Cancer type	Molecular marker	Circle or provide result
Bladder (cont'd)	NTRK Fusion	☐Positive ☐Negative ☐Not Reported ☐Unknown
Bone and Soft Tissue Cancers	Microsatellite Instability	☐MSI-L ☐dMMR/MSI-H ☐Not Reported ☐Unknown
(including Sarcoma)	NTRK Fusion	<ul><li>□Positive</li><li>□Not Reported</li><li>□Unknown</li></ul>
Brain	19q Status	□Deleted    □No Deletion    Not Reported     □Unknown
	1p Status	□Deleted □No Deletion □Not Reported □Unknown
	CD20 Status	□Positive □Negative □Not Reported □Unknown
	MGMT Promotor Status	<ul><li>☐Methylated</li><li>☐Indeterminate</li><li>☐Not Reported</li><li>☐Unknown</li></ul>
	Microsatellite Instability	
	NTRK Fusion	☐ Positive ☐ Negative ☐ Not Reported ☐ Unknown
Breast	Microsatellite Instability	
	BRCA 1 Status	☐Germline Mutation present ☐Not Reported ☐Unknown ☐Wild type/no mutation
	BRCA 2 Status	☐ Germline Mutation present ☐ Not Reported ☐ Somatic Mutation present ☐ Unknown ☐ Wild type/no mutation
	Menopausal Status	☐Premenopausal ☐Perimenopausal ☐Postmenopausal ☐Not Reported ☐Unknown ☐Does Not Apply/Patient is male
	OncotypeDx <sup>®</sup> Breast	□Low □Intermediate or High □Not reported □Unknown
	Estrogen Receptor	<ul><li>□Positive</li><li>□Not Reported</li><li>□Unknown</li></ul>
	HER2/NEU	□ Equivocal □ FISH or CISH Equivocal □ FISH or CISH Negative □ FISH or CISH Positive □ IHC 1+ □ IHC 2+ □ IHC 3+ □ IHC negative □ IHC Equivocal □ Negative □ Not Reported □ Unknown



Cancer type	Molecular marker	Select or provide re	esult	
Breast (cont.)	NTRK Fusion	□Positive □Unknown	□Negative	□Not Reported
	PD-L1 Expression (TPS)	□1%-49.9% □Less than 1% □Not Reported	□Greater or equ □Negative □Unknown	ual to 50%
	Progesterone Receptor	□Positive □Unknown	□Negative	□Not Reported
Cervical	Microsatellite Instability	□MSI-L □Unknown	□dMMR/MSI-H	□Not Reported
	NTRK Fusion	□Positive □Unknown	□Negative	□Not Reported
	PD-L1 Expression (CPS)	□1%-19.9% □Less than 1%	☐Greater or equ☐Not Reported	ual to 20% □Unknown
Colon	Microsatellite Instability	□MSI-L □Unknown	□dMMR/MSI-H	□Not Reported
	k-ras Genotype	□Wild Type □Unknown	□Mutated	□Not Reported
	BRAF Status	□V600E Mutation □Wild Type □N	<del></del>	V600K Mutation Unknown
	n-ras Genotype	□Wild Type □Unknown	□Mutated	□Not Reported
	NTRK Fusion	□Positive □Unknown	□Negative	□Not Reported
Esophageal	HER2/NEU	☐FISH or CISH Neg	IHC 2+ □IH IHC Equivocal	ocal or CISH Positive IC 3+ □Negative
	PD-L1 Expression (CPS)	☐1%-19.9% ☐Less than 1%	□Greater or equ □Not Reported	
	Microsatellite Instability	□MSI-L □Unknown	□dMMR/MSI-H	□Not Reported
	NTRK Fusion	□Positive □Unknown	□Negative	□Not Reported
Еуе	Microsatellite Instability	□MSI-L □Unknown	□dMMR/MSI-H	□Not Reported
	NTRK Fusion	□Positive □Unknown	□Negative	□Not Reported
Gall Bladder	Microsatellite Instability	□MSI-L □Unknown	□dMMR/MSI-H	□Not Reported



Cancer type	Molecular marker	Select or provide result
Gall Bladder (cont.)	NTRK Fusion	☐Positive ☐Negative ☐Not Reported ☐Unknown
Gastric (Stomach)	HER2/NEU	□ Equivocal □ FISH or CISH Equivocal □ FISH or CISH Negative □ FISH or CISH Positive □ IHC 1+ □ IHC 2+ □ IHC 3+ □ IHC Negative □ IHC Reported □ Unknown
	PD-L1 Expression (CPS)	☐1%-19.9% ☐Greater or equal to 20% ☐Less than 1% ☐Not Reported ☐Unknown
	Microsatellite Instability	☐MSI-L ☐dMMR/MSI-H ☐Not Reported ☐Unknown
	NTRK Fusion	☐Positive ☐Negative ☐Not Reported ☐Unknown
Gastrointestinal Stromal Tumor (GIST)	GIST Risk	☐ High Intermediate ☐ Low ☐ Unknown
	c-kit Status	□Exon 11 mutation present □Exon 9 mutation present □No Mutation □Not Reported □Unknown
	Microsatellite Instability	☐MSI-L ☐dMMR/MSI-H ☐Not Reported ☐Unknown
	NTRK Fusion	☐Positive ☐Negative ☐Not Reported ☐Unknown
	Imatinib resistant or intolerant	□Yes □No □Not Reported □Unknown
	Sunitinib lesistant	□Yes □No □Not Reported □Unknown
Head and Neck	Microsatellite Instability	☐MSI-L ☐dMMR/MSI-H ☐Not Reported ☐Unknown
	NTRK Fusion	☐Positive ☐Negative ☐Not Reported ☐Unknown
	PD-L1 Expression (CPS)	□1%-19.9% □Greater or equal to 20% □Less than 1% □Not Reported Unknown
Kidney	Microsatellite Instability	☐MSI-L ☐dMMR/MSI-H ☐Not Reported ☐Unknown
	NTRK Fusion	☐Positive ☐Negative ☐Not Reported ☐Unknown



Cancer type	Molecular marker	Select or provide result
Kidney (cont.)	Prior Therapy	□Axitinib       □Bevacizumab         □Everolimus       □Interferon alfa         □Interleukin-2       □Pazopanib       □Temsirolimus         □Sorafenib       □Sunitinib       □No Prior         □Unknown       □Not Reported       Therapy
	Renal Cancer Risk	☐Good Risk ☐Intermediate Risk ☐Not Reported ☐Poor Risk ☐Unknown
	Wilms Risk	☐ Favorable ☐ Non-favorable ☐ Unknown
Leukemia	CD20 Status	☐Positive ☐Negative ☐Not Reported ☐Unknown
	Imatinib Resistant or Intolerant	☐Yes ☐No ☐Not Reported ☐Unknown
	Philadelphia Chromosome	☐ Positive ☐ Negative ☐ Not Reported ☐ Unknown
	T315I	☐Positive ☐Negative ☐Not Reported ☐Unknown
	CD19 Status	☐Positive ☐Negative ☐Not Reported ☐Unknown
	CD22 Status	☐Positive ☐Negative ☐Not Reported ☐Unknown
	HIV-Associated Lymphoma	☐Positive ☐Negative ☐Not Reported ☐Unknown
	Nodal Size	☐Total size >= 10 cm ☐Total size < 10 cm ☐Unknown
	Serum LDH Level	☐ High, above normal limits ☐ Within normal limits ☐ Unknown
	CD33 Status	□Positive □Negative □Not Reported □Unknown
	FLT3 Mutation	☐ Positive ☐ Negative ☐ Not Reported ☐ Unknown
	IDH1 Mutation	☐Positive ☐Negative ☐Not Reported ☐Unknown
	IDH2 Mutation	☐Positive ☐Negative ☐Not Reported ☐Unknown
	APL Risk	☐ High ☐ Intermediate ☐ Low ☐ Unknown ☐ Not Reported
	White Blood Cell Count	□<=10,000 cells/mcl □>10,000 cells/mcl □Unknown
	CD30 Status	☐ Positive ☐ Negative ☐ Not Reported ☐ Unknown



Cancer type	Molecular marker	Select or provide result
	11q Deletion	☐Absent ☐Present ☐Not Reported ☐Unknown
	17p Deletion	☐Absent ☐Present ☐Not Reported ☐Unknown
	TP53 Status	□Mutation Absent       □Mutation Present         □Not Reported       □Unknown
	CML Phase	□ Accelerated Phase □ Chronic Phase □ Lymphoid Blast Phase □ Myeloid Blast Phase □ Unknown
	BRAF Status	□V600E Mutation □V600K Mutation □Wild Type □Not Reported □Unknown
	Microsatellite Instability	☐MSI-L ☐dMMR/MSI-H ☐Not Reported ☐Unknown
Liver	Microsatellite Instability	☐MSI-L ☐dMMR/MSI-H ☐Not Reported ☐Unknown
	NTRK Fusion	☐Positive ☐Negative ☐Not Reported ☐Unknown
Lung	ALK Status	☐ Positive ☐ Negative ☐ Not Reported ☐ Unknown
	BRAF Status	□V600E Mutation □V600K Mutation □Wild Type □Not Reported □Unknown
	EGFR	□Wild Type □Mutated □Not Reported □Unknown
	EGFR T790M Mutation	☐Positive ☐Negative ☐Not Reported ☐Unknown
	MET Amplification	☐Positive ☐Negative ☐Not Reported ☐Unknown
	PD-L1 Expression (TPS)	☐ 1% to 49% ☐ Greater or equal to 50% ☐ Less than 1% ☐ Negative ☐ Not Reported ☐ Unknown
	RET Gene Rearrangement	☐Absent ☐Present ☐Not Reported ☐Unknown
	ROS1 Rearrangement	☐ Positive ☐ Negative ☐ Not Reported ☐ Unknown
	Microsatellite Instability	☐MSI-L ☐dMMR/MSI-H ☐Not Reported ☐Unknown
	NTRK Fusion	☐Positive ☐Negative ☐Not Reported ☐Unknown



Cancer type	Molecular marker	Select or provide result
Lymphoma/ Lymphoproliferative	ALK Status	☐Positive ☐Negative ☐Not Reported ☐Unknown
Diseases	Nodal Size	☐Total size >= 10 cm ☐Total size < 10 cm ☐Unknown
	Serum LDH Level	<ul><li>☐ High, above normal limits</li><li>☐ Not Reported</li><li>☐ Unknown</li></ul>
	HIV-Associated Lymphoma	☐Yes ☐No ☐Not Reported ☐Unknown
	11q Deletion	☐Absent ☐Present ☐Not Reported ☐Unknown
	17p Deletion	<ul><li>□Absent □Present □Not Reported</li><li>□Unknown</li></ul>
	TP53 Status	<ul><li>☐Mutation Absent</li><li>☐Mutation Present</li><li>☐Unknown</li></ul>
	BRAF Status	□V600E Mutation □V600K Mutation □Wild Type □Not Reported □Unknown
	Transplant Candidate	☐Yes ☐No ☐Not Reported ☐Unknown
	CD20 Status	☐Positive ☐Negative ☐Not Reported ☐Unknown
	CD30 Status	<ul><li>□Positive  □Negative  □Not Reported</li><li>□Unknown</li></ul>
	CD52 Status	□Positive □Negative □Not Reported □Unknown
Melanoma	BRAF Status	□V600E Mutation □V600K Mutation □Wild Type □Not Reported □Unknown
	c-kit Status	☐ Exon 11 mutation present ☐ Unknown ☐ Exon 9 mutation present ☐ Not Reported
	Microsatellite Instability	☐MSI-L ☐dMMR/MSI-H ☐Not Reported ☐Unknown
	NTRK Fusion	☐Positive ☐Negative ☐Not Reported ☐Unknown
Mesothelioma	Microsatellite Instability	☐MSI-L ☐dMMR/MSI-H ☐Not Reported ☐Unknown
	NTRK Fusion	□Positive □Negative □Not Reported □Unknown



Cancer type	Molecular marker	Select or provide result
Myelodysplastic Syndrome (MDS)	PDGFR Mutations	☐Absent ☐Present ☐Not Reported ☐Unknown
	Risk	☐ High ☐ INT-1 ☐ INT-2 Intermediate ☐ Low ☐ Very High
	Transplant Candidate	☐Yes ☐No ☐Not Reported ☐Unknown
	Cytogenetic Abnormalities	<ul><li>□Absent □Present □Not Reported</li><li>□Unknown</li></ul>
	5q Deletion (5q-)	<ul><li>□Absent □Present □Not Reported</li><li>□Unknown</li></ul>
Myeloma	Transplant Candidate	☐Yes ☐No ☐Not Reported ☐Unknown
Myeloproliferative Disorders	PDGFR Mutations	☐Absent ☐Present ☐Not Reported ☐Unknown
Ovarian	Microsatellite Instability	☐MSI-L ☐dMMR/MSI-H ☐Not Reported ☐Unknown
	NTRK Fusion	☐Positive ☐Negative ☐Not Reported ☐Unknown
	BRCA1 Status	☐Germline Mutation Present ☐Not Reported ☐Somatic Mutation Present ☐Unknown ☐Wild Type/No Mutation
	BRCA2 Status	☐Germline Mutation present ☐Not Reported ☐Somatic Mutation present ☐Unknown ☐Wild Type/No Mutation
	Platinum Resistant/Refractory	☐Yes ☐No ☐Not Reported ☐Unknown
	Paclitaxel-Resistant	☐Yes ☐No ☐Not Reported ☐Unknown
Pancreatic	Microsatellite Instability	☐MSI-L ☐dMMR/MSI-H ☐Not Reported ☐Unknown
	NTRK Fusion	□Positive □Negative □Not Reported □Unknown
Penile	Microsatellite Instability	☐MSI-L ☐dMMR/MSI-H ☐Not Reported ☐Unknown
	NTRK Fusion	□Positive □Negative □Not Reported □Unknown
Prostate	Castration-Resistant	☐Yes ☐No ☐Not Reported ☐Unknown
	Prostate Cancer Recurrence Risk	☐ Favorable ☐ Intermediate ☐ High ☐ Low ☐ Regional ☐ Unfavorable ☐ Intermediate ☐ Very High ☐ Very Low ☐ Not Reported ☐ Unknown



Cancer type	Molecular marker	Select or provi	de result	
	Microsatellite Instability	□MSI-L □Unknown	□dMMR/MSI-H	□Not Reported
	NTRK Fusion	□Positive □Unknown	□Negative	□Not Reported
Rectal	Microsatellite Instability	□MSI-L □Unknown	□dMMR/MSI-H	□Not Reported
	NTRK Fusion	□Positive □Unknown	□Negative	□Not Reported
	n-ras Genotype	□Wild Type □Unknown	□Mutated	□Not Reported
	k-ras Genotype	□Wild Type □Unknown	□Mutated	□Not Reported
	BRAF Status	□V600E Mutat		□V600K Mutation □Unknown
Renal Pelvis and Ureter Cancers	Microsatellite Instability	□MSI-L □Unknown	□dMMR/MSI-H	□Not Reported
	NTRK Fusion	□Positive □Unknown	□Negative	□Not Reported
	Platinum Resistant/Refractory	□Yes □No	□Not Reported	□Unknown
Skin (Non-Melanoma)	Microsatellite Instability	□MSI-L □Unknown	□dMMR/MSI-H	□Not Reported
	NTRK Fusion	□Positive □Unknown	□Negative	□Not Reported
Small Intestine	n-ras genotype	□Wild Type □Unknown	□Mutated	□Not Reported
	k-ras genotype	□Wild Type □Unknown	□Mutated	□Not Reported
	Obstruction at resection	□Yes □No	□Not Reported	□Unknown
	Perforation	□Yes □No	□Not Reported	□Unknown
	T4 Lesion	□Yes □No	□Not Reported	□Unknown
	Microsatellite Instability	□MSI-L □Unknown	□dMMR/MSI-H	□Not Reported
	NTRK Fusion	□Positive □Unknown	□Negative	□Not Reported
Testicular	Microsatellite Instability	□MSI-L □Unknown	□dMMR/MSI-H	□Not Reported
	NTRK Fusion	□Positive □Unknown	□Negative	□Not Reported



Cancer type	Molecular marker	Select or provide result
	Platinum Resistant/Refractory	☐Yes ☐No ☐Not Reported ☐Unknown
Thymic	Microsatellite Instability	☐MSI-L ☐dMMR/MSI-H ☐Not Reported ☐Unknown
	NTRK Fusion	□Positive □Negative □Not Reported □Unknown
Thyroid	Microsatellite Instability	☐MSI-L ☐dMMR/MSI-H ☐Not Reported ☐Unknown
	NTRK Fusion	□Positive □Negative □Not Reported □Unknown
	BRAF status	□V600E Mutation □V600K Mutation □Wild Type □Not Reported □Unknown
Unknown Primary	Microsatellite Instability	☐MSI-L ☐dMMR/MSI-H ☐Not Reported ☐Unknown
	NTRK Fusion	□Positive □Negative □Not Reported □Unknown
Urethral	Microsatellite Instability	☐MSI-L ☐dMMR/MSI-H ☐Not Reported ☐Unknown
	NTRK Fusion	☐Positive ☐Negative ☐Not Reported ☐Unknown
Uterine (Endometrial)	Estrogen Receptor	☐Positive ☐Negative ☐Not Reported ☐Unknown
	HER2/NEU	□ Equivocal □ FISH or CISH Equivocal □ FISH or CISH Negative □ FISH or CISH Positive □ IHC 1+ □ IHC 2+ □ IHC 3+ □ IHC negative □ IHC Equivocal □ Negative □ Not Reported □ Unknown
	Progesterone Receptor	☐Positive ☐Negative ☐Not Reported ☐Unknown
	Microsatellite Instability	☐MSI-L☐dMMR/MSI-H ☐Not Reported ☐Unknown
	NTRK Fusion	☐Positive ☐Negative ☐Not Reported ☐Unknown
Vaginal	Microsatellite Instability	☐MSI-L ☐dMMR/MSI-H ☐Not Reported ☐Unknown
	NTRK Fusion	☐Positive ☐Negative ☐Not Reported ☐Unknown
Vulvar	Microsatellite Instability	☐MSI-L ☐dMMR/MSI-H ☐Not Reported ☐Unknown
	NTRK Fusion	☐Positive ☐Negative ☐Not Reported ☐Unknown



Cancer type	Molecular marker	Select or provide result	
	PD-L1 Expression (CPS)	☐1 to 19.99% ☐Less than 1%	<ul><li>☐Greater than or equal to 20%</li><li>☐Not Reported ☐Unknown</li></ul>
Waldenström's Macroglobulinemia / Lymphoplasmacytic Lymphoma	Transplant candidate	□Yes □No	□Not Reported □Unknown